used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs
and their effect as therapeutics in the pandemic, including structural classification, outcomes
in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent
immune escape. We show how the omicron (B. 1.1. 529) variant of concern has reset
treatment strategies so far, discuss future developments that could lead to improved …